Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan 1;110(1):239-243.
doi: 10.3324/haematol.2024.285934.

Prognostic stratification in venetoclax-based acute myeloid leukemia treatments: the molecular prognostic risk signature tested in a real-world setting

Gaia Ciolli  1 , Matteo Piccini  1 , Francesco Mannelli  2 , Giacomo Gianfaldoni  1 , Barbara Scappini  1 , Laura Fasano  1 , Francesca Crupi  1 , Elisa Quinti  1 , Andrea Pasquini  1 , Jessica Caroprese  1 , Giada Rotunno  3 , Fabiana Pancani  3 , Leonardo Signori  3 , Chiara Maccari  3 , Fiorenza I Vanderwert  3 , Paola Guglielmelli  2 , Alessandro M Vannucchi  4
Affiliations

Prognostic stratification in venetoclax-based acute myeloid leukemia treatments: the molecular prognostic risk signature tested in a real-world setting

Gaia Ciolli et al. Haematologica. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Overall survival predicted by the molecular prognostic risk signature and Krüger’s model in patients with acute myeloid leukemia. (A, B) Overall survival predicted by the molecular prognostic risk signature in patients with newly diagnosed acute myeloid leukemia (A) and in those with relapsed or refractory disease (B). (C) Overall survival according to Krüger’s model in the relapsed/refractory cohort. (D) C-index comparisons. ND: newly diagnosed; mPRS: molecular prognostic risk signature; RR: relapsed or refractory; ELN: European LeukemiaNet; OS: overall survival; 95% CI: confidence interval; HR: hazard ratio.
Figure 2.
Figure 2.
Event-free survival predicted by the molecular prognostic risk signature and Krüger’s model in patients with acute myeloid leukemia. (A, B) Event-free survival predicted by the molecular prognostic risk signature in patients with newly diagnosed acute myeloid leukemia (A) and in those with relapsed or refractory disease (B). (C) Event-free survival according to Krüger’s model in the relapsed/refractory cohort. (D) C-index comparisons. ND: newly diagnosed; mPRS: molecular prognostic risk signature; RR: relapsed or refractory; ELN: European LeukemiaNet; EFS: event-free survival; 95% CI: confidence interval; HR: hazard ratio.
See this image and copyright information in PMC

References

    1. Döhner H, Wei AH, Appelbaum FR, et al. . Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345-1377. - PubMed
    1. Bataller A, Bazinet A, DiNardo CD, et al. . Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax. Blood Adv. 2024;8(4):927-935. - PMC - PubMed
    1. Döhner H, Pratz KW., DiNardo CD, et al. . ELN risk stratification is not predictive of outcomes for treatment-naïve patients with acute myeloid leukemia treated with venetoclax and azacitidine. Blood. 2022;140(Supplement 1):1441-1444.
    1. DiNardo CD, Tiong IS, Quaglieri A, et al. . Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood. 2020;135(11):791-803. - PMC - PubMed
    1. Krüger K, Wichmann M, Gabdoulline R, et al. . Predictors of response and outcome in patients with refractory/relapsed acute myeloid leukemia receiving venetoclax with non-intensive chemotherapy. Hemasphere. 2023;7(Suppl):e19815ef.

LinkOut - more resources